Medical Device & Biotech
Patent Attorney in Austin, Texas
Protecting medical device and biotech innovations with technical precision — backed by advanced medical patent experience and over 17 years of USPTO practice.
Home → Practice Areas → Medical Device & Biotech Patents
The Physics Behind Medical Device Innovation
Medical device patent prosecution is different from other technology areas in a way that most practitioners understate: the underlying physics of medical devices — the optics of imaging systems, the electromagnetics of wireless biosensors, the mechanics of minimally invasive instruments, the signal processing mathematics of diagnostic algorithms — determines what is patentable, how claims should be structured, and how USPTO examiners in the medical device art units will evaluate the prior art. An attorney who understands that underlying physics engages with medical device patent prosecution at a fundamentally different level than one who approaches it through legal framework alone.
My physics degree from the University of Texas at Austin — where I studied quantum mechanics, classical dynamics, and tensor calculus — gives me the mathematical and physical foundation to understand medical device inventions at exactly that level. When a medical device engineer describes a novel optical coherence tomography approach, a new piezoelectric actuator design for surgical robotics, or a machine learning algorithm for detecting arrhythmias in continuous cardiac monitoring data, I understand what they are describing technically — not as an intelligent non-expert interpreting a technical briefing, but as someone who has worked with the underlying physics in engineering contexts.
That technical starting point matters for the quality of medical device patents in several specific ways. It means the prior art searching I conduct before drafting identifies the closest references in the physics and engineering literature — not just in medical device patent databases, but in physics journals, biomedical engineering conference proceedings, and the electrical and mechanical engineering literature where the most technically relevant prior art for sophisticated medical devices is frequently found. It means the specifications I draft accurately describe the physical principles underlying the innovation — which is essential for supporting broad claims and satisfying the enablement requirement for complex medical device inventions. And it means the claims I draft capture the genuine technical innovation rather than a layperson's description of what the device does from the outside.
Diagnostic Systems — Imaging, Sensing, and AI-Enabled Detection
Diagnostic medical devices represent one of the most technically sophisticated and most patent-active categories in medical device innovation — encompassing imaging systems that push the boundaries of physics and signal processing, biosensors that detect physiological parameters at the molecular level, and AI-powered diagnostic algorithms that interpret complex physiological data in ways that augment or replace clinical judgment.
Optical diagnostic systems — including optical coherence tomography, fluorescence imaging, photoacoustic sensing, and hyperspectral imaging for tissue characterization — sit directly at the intersection of my optics experience and medical device patent practice. The patent landscape for optical diagnostic systems is technically dense, with significant prior art in the physics and biomedical optics literature that extends well beyond conventional patent databases. Prior art searching for optical diagnostic device applications requires genuine familiarity with the optical physics literature — specifically, the ability to evaluate technical papers in biomedical optics journals against specific patent claim elements at a level of technical precision that identifies true novelty versus incremental variation. My optics background enables that level of evaluation.
AI-enabled diagnostic systems present both the most commercially significant patent opportunities and the most complex prosecution challenges in the current medical device landscape. The intersection of machine learning patentability under Alice/Mayo with medical device regulatory considerations — specifically, the FDA's increasing scrutiny of AI/ML-based Software as a Medical Device (SaMD) — creates a strategic environment where patent claim strategy and regulatory pathway planning need to be coordinated rather than pursued independently. I advise medical device AI companies on patent claim strategies that protect the core algorithmic and architectural innovations of their diagnostic systems while accommodating the technical specificity that both Alice compliance and FDA's predetermined change control protocol documentation require.
Surgical Instruments, Robotics, and Implantable Devices
Surgical instrument and robotic surgery patents occupy a distinctive position in the medical device IP landscape — technically sophisticated mechanical and electromechanical inventions that require both engineering precision in claim drafting and regulatory awareness about the specific device categories involved. From minimally invasive laparoscopic instruments to fully autonomous surgical robots to permanently implanted neuromodulation devices, this category spans an extraordinary range of technical complexity and clinical application.
The mechanical engineering content of surgical instrument patents — the kinematics of articulating end effectors, the force feedback mechanisms of robotic surgical systems, the materials science of implantable device biocompatibility — draws on the physics and engineering foundations that my UT Austin training provided. Classical mechanics, materials deformation analysis, and mechanical system dynamics are not abstract academic subjects in surgical robotics patent prosecution — they are the technical substance of the patent claims, and getting them right requires the kind of foundational physics and engineering understanding that shapes how I approach this work.
Implantable device patents — for cardiac rhythm management devices, neuromodulation systems, cochlear implants, and the emerging category of bioelectronic medicines — involve a specific intersection of electrical engineering, materials science, biocompatibility, and clinical medicine that creates multi-dimensional patent strategy opportunities. A well-structured implantable device patent portfolio covers not just the device itself but the methods of using it, the manufacturing processes that achieve required biocompatibility, the software algorithms that control its operation, and the external programmer systems that configure and monitor it. I develop comprehensive implantable device patent strategies that protect each of these dimensions rather than leaving commercially significant aspects of the innovation unprotected.
Wearable Health Technology and Connected Medical Devices
Wearable health technology — continuous glucose monitors, wearable cardiac monitors, smartwatch-based health sensors, and the rapidly expanding category of digital therapeutics — represents one of the fastest-growing segments of medical device innovation and one of the most complex from a patent strategy perspective. These devices sit at the intersection of hardware innovation, signal processing algorithms, wireless communication systems, and mobile software — each dimension offering patent opportunities and each dimension requiring specific technical expertise to protect effectively.
The physiological sensing innovations in wearable health devices — novel electrode configurations for bioimpedance sensing, optical pulse oximetry improvements, novel motion artifact compensation algorithms, and new approaches to continuous analyte monitoring — involve the kind of sensor physics and signal processing engineering that my technical background specifically equips me to handle. Distinguishing genuinely novel sensing approaches from the dense prior art in physiological sensing — which spans medical device patents, academic biomedical engineering literature, and consumer electronics patents from companies like Apple, Fitbit, and Garmin — requires technical understanding of what makes a sensing approach physically different from prior approaches rather than just superficially different.
The software and connectivity dimensions of connected medical devices — the mobile apps that display and act on device data, the cloud platforms that aggregate and analyze patient data, the AI algorithms that generate clinical insights from device outputs — all require patent strategies that integrate medical device prosecution practice with software patent practice. Many of the most valuable innovations in connected health devices live precisely at this hardware-software interface, and protecting them requires an attorney who is equally comfortable with the device hardware claims and the software algorithm claims that together constitute the complete competitive protection for the innovation.
Regulatory Pathway Integration With Patent Strategy
The intersection of FDA regulatory pathways and patent strategy is one of the most practically important considerations in medical device IP planning — and one that patent attorneys without specific medical device experience regularly underestimate in its significance. The timing of patent filings, the content of patent specifications, and the scope of patent claims all interact with FDA regulatory submissions in ways that can either strengthen or complicate the company's overall IP position.
510(k) clearance submissions for Class II medical devices become public records that constitute prior art once published. A company that files a detailed 510(k) submission describing the technical operation of its device before filing patent applications has potentially disclosed its invention publicly — starting the one-year US grace period and potentially eliminating international patent rights in absolute novelty jurisdictions. The coordination between patent filing timing and 510(k) submission timing is therefore a concrete strategic decision that medical device companies need to make explicitly rather than allowing to happen by default.
PMA applications for Class III medical devices involve an even more extensive technical disclosure that creates similar prior art concerns — with the additional consideration that PMA submissions often describe device performance data and clinical results that may themselves constitute patentable subject matter that should be protected before disclosure. The clinical data, patient outcomes, and real-world performance characterizations that PMA submissions require can reveal novel uses, novel device parameters, and novel patient population characteristics that warrant patent protection separate from the underlying device hardware.
I advise medical device clients on patent filing strategy that coordinates with their FDA regulatory timeline — ensuring that patent applications are filed before regulatory submissions create prior art issues, that the technical descriptions in patent specifications are consistent with the technical descriptions in regulatory submissions, and that the scope of patent claims covers the device as it will actually be used in the cleared or approved clinical indication rather than a hypothetical version that predates regulatory interaction.
Austin's Health Technology Innovation Landscape
Austin's health technology sector has undergone a genuine transformation over the past decade — evolving from a city known primarily for software and semiconductor innovation to one with a substantial and growing medical device and health AI ecosystem supported by UT Dell Medical School, UT's engineering and computer science research programs, Ascension Seton's clinical research infrastructure, and a venture capital community that has developed real sophistication in evaluating health technology investment opportunities.
The health technology companies I work with in Austin span the full range of the sector's diversity — from early-stage startups developing novel biosensing technologies coming out of UT research labs, to growth-stage medical AI companies building clinical decision support systems for hospital systems, to established medical device companies with existing product lines seeking to protect next-generation innovations against well-capitalized competition. Each represents a different IP strategy challenge and a different patent portfolio objective — and each benefits from patent counsel who understands both the technical substance of what they are building and the commercial context in which they are building it.
The convergence of Austin's semiconductor and software expertise with its health technology ambitions is creating a category of medical devices that did not meaningfully exist a decade ago — AI-native diagnostic platforms, implantable computing systems, and precision medicine tools that combine genomic analysis, biosensing, and machine learning in ways that require genuinely cross-disciplinary patent expertise to protect. This convergence is where my specific combination of semiconductor engineering background, optics experience, and software systems knowledge is most directly applicable to medical device patent practice — covering the full technical scope of innovations that span hardware physics, embedded computing, and AI algorithms in a single integrated system.
Call or text (512) 293-0710, email sconnolly@austin-patent-attorney.com, or fill out the contact form to discuss your medical device or biotech patent needs.
[ Medical & Biotech Patent FAQs — Austin, Texas ]
Question: How are medical device patents different from other patents?
Answer: Medical device patents require the same technical precision as any other patent but operate in a highly regulated industry. Many medical devices incorporate significant software components requiring an attorney who understands both hardware and software patent strategy. My background in physics and optics — including experience with sensor technologies — gives me the technical foundation to protect complex medical device innovations comprehensively.
Question: Can I patent medical device software and AI components?
Answer: Yes — the software and AI components of a medical device are often where the core innovation lives and they are absolutely patentable with the right claim strategy. I have experience protecting both the hardware and software aspects of medical devices comprehensively, including diagnostic AI algorithms, machine learning models for patient monitoring, and clinical decision support systems.
Question: What is a 510(k) predicate device and how does it affect my medical device patent strategy?
Answer: A 510(k) predicate device is a previously FDA-cleared device that your new device is substantially equivalent to — the regulatory foundation that supports 510(k) clearance rather than the more rigorous PMA approval pathway. The relationship between your predicate device and your patent strategy is significant in both directions. If your device is substantially equivalent to a predicate for regulatory purposes, your patent claims must distinguish it sufficiently from that predicate to establish novelty and non-obviousness — a distinction that needs to be real and technically specific, not merely cosmetic. Conversely, the specific improvements over the predicate that establish substantial equivalence for FDA purposes — the safety and effectiveness data supporting your 510(k) — often identify exactly the technical innovations worth patenting. I advise medical device clients to develop patent strategy and 510(k) strategy in parallel rather than sequentially, because the decisions made in each process affect the other.
Question: How do you patent a medical device that uses an AI algorithm for diagnostic decision support?
Answer: AI-enabled medical diagnostic devices sit at the intersection of multiple complex IP and regulatory frameworks — FDA's SaMD regulations, the Alice/Mayo patent eligibility doctrine for AI claims, and the specific technical requirements of medical diagnostic patent prosecution. The patent strategy must navigate all three simultaneously. From a patent drafting perspective, the claims need to describe specific technical implementations of the AI system — the particular neural network architecture, the specific training methodology, the novel feature extraction approach — rather than claiming the diagnostic conclusion at a high level of abstraction. From a regulatory coordination perspective, the predetermined change control protocol that FDA now requires for adaptive AI medical devices describes future modifications to the AI system that the continuation patent strategy should anticipate and support. I coordinate these dimensions specifically for medical AI clients rather than treating them as separate legal and regulatory exercises.
Question: What is a supplementary protection certificate and does it apply to medical devices in the United States?
Answer: Supplementary protection certificates — available in Europe and certain other jurisdictions to extend effective patent protection for products subject to lengthy regulatory approval delays — do not have a direct US equivalent for medical devices. In the United States, patent term extension under 35 U.S.C. § 156 provides compensation for time lost during FDA regulatory review for certain regulated products including medical devices subject to PMA approval. The extension is calculated based on the time spent in regulatory review after the first permitted commercial marketing of the device, subject to a maximum five-year extension and a maximum total term of 14 years from FDA approval. For medical device companies with PMA-track products where the regulatory timeline meaningfully reduces effective patent term, section 156 extension should be evaluated as part of the overall patent lifecycle strategy from the time of initial patent filing.
Question: My medical device has both hardware and software innovations, including a companion mobile app — do I need separate patents for each?
Answer: Not necessarily separate patents, but your patent strategy should specifically address every dimension. A single, well-drafted application can include claims directed at the hardware architecture, the software and app-based algorithms, the system as a whole, and the methods of using the device — layered protection in one filing rather than four separate patents. System-level claims cover the integrated device-app combination as a whole. Device claims cover the hardware innovations in the physical medical device. Method claims cover the diagnostic or therapeutic process performed by the combined system. Software claims cover the app's specific algorithmic innovations for data processing, AI-assisted interpretation, or user interface interactions that produce clinically meaningful results. Covering all four claim types gives you the ability to enforce against competitors who copy the system, the device alone, or just the app functionality — without needing to copy the entire integrated product. Continuation applications are often valuable on top of this foundation, letting you pursue additional claims directed at specific aspects of the device as they become commercially significant. I draft medical device applications to comprehensively cover this full technical scope from the outset — hardware, software, method, and system claims together — maximizing protection across every commercially relevant dimension.
Question: What IP considerations are specific to medical device startups coming out of UT Dell Medical School in Austin?
Answer: UT Dell Medical School spinout companies face the same IP considerations as other university spinouts with some additional dimensions specific to the medical school context. The university's IP policy governs inventions made by faculty, residents, and research staff using university resources — which means the IP assignment chain for a medical school spinout typically runs from individual inventors to UT Austin's Office of Technology Commercialization and then to the spinout company through a license or assignment agreement. Clinical observations, patient data, and medical discoveries made in the course of patient care rather than formal research present specific ownership questions that differ from traditional research inventions. And the medical device regulatory pathway that the startup will pursue affects the IP timeline — PMA-track devices warrant different patent filing strategies than 510(k)-track devices. I advise Austin medical device spinouts on IP strategy that coordinates all of these dimensions from the earliest stage of company formation.
Question: How do you handle patent prosecution for a medical device that underwent significant design changes during clinical trials?
Answer: Design changes during clinical development are common and create specific patent prosecution considerations. If the design changes are improvements on or variations of what was disclosed in the original patent application, continuation and continuation-in-part applications can capture the evolved design while preserving the original filing date for subject matter disclosed in the original application. If the clinical trial revealed unexpected results — better than expected performance, novel mechanisms of action not anticipated in the original filing — those unexpected results can support non-obviousness arguments in prosecution and may warrant separate patent filings on the specific discoveries. The key is maintaining communication between the clinical development team and patent counsel throughout the trial process — not waiting until the device is finalized to assess what additional IP protection is warranted based on what was learned.
Question: What is the Freedom to Operate landscape for a new medical device entering the Austin health technology market?
Answer: Austin's health technology market involves both local competitors and the major medical device companies — Medtronic, Abbott, Boston Scientific, Stryker, and others — that hold extensive patent portfolios in virtually every device category. A realistic FTO assessment for a new Austin medical device startup must account for both the local competitive landscape and the major company portfolios that cover foundational medical device technologies. My approach to medical device FTO analysis extends beyond standard patent database searching to include the specific technical literature that medical device patent examiners use as prior art — IEEE EMBS publications, SPIE biomedical optics proceedings, Journal of Medical Devices, and regulatory submissions that constitute public disclosures. The FTO analysis result informs both the freedom to commercialize the device and the claim drafting strategy for the startup's own patents — designing around identified risk areas while claiming the specific innovations that distinguish the device from existing solutions.
Question: How does the FDA's Software as a Medical Device (SaMD) framework interact with patent strategy?
Answer: FDA's SaMD framework — governing AI and software-based medical devices including diagnostic algorithms, clinical decision support systems, and monitoring applications — creates specific IP strategy considerations. The predetermined change control protocol (PCCP) that FDA now requires for adaptive AI medical devices describes how the software will be modified over time, which can inform the continuation patent strategy — filing continuation applications as the software evolves through PCCP-approved modifications. FDA's Software Function Table categories also map roughly to patent claim categories, helping identify which functional innovations deserve patent protection priority.
Question: Can I patent a medical device that incorporates a naturally occurring biological process?
Answer: Medical devices that measure, detect, or interact with naturally occurring biological processes are generally patentable — the device itself and the methods of using it are human-made inventions even if they interface with natural processes. The challenge arises when claims are drafted so broadly that they effectively claim the natural process itself rather than the specific technical system for detecting or interacting with it. A patent claim directed at "a system for measuring blood glucose comprising specific technical sensor elements and processing algorithms" is patentable. A claim directed at "detecting glucose in blood" without specifying the technical means is essentially claiming a natural phenomenon and is not patentable. Precise claim drafting that focuses on the technical system rather than the biological target is the key to protecting medical device innovations that interact with naturally occurring processes.
Question: What special considerations apply to patents on combination products — devices that include drugs or biologics?
Answer: Combination products — medical devices that incorporate drug or biologic components, such as drug-eluting stents, combination drug-device prefilled syringes, or transdermal drug delivery systems — create layered patent strategy opportunities because both the device component and the pharmaceutical component may be independently patentable. The interaction between device patents, drug composition patents, method of treatment patents, and formulation patents creates a multi-dimensional IP landscape that requires coordinated strategy. I advise combination product developers on comprehensive IP strategies that protect all dimensions of their innovations rather than focusing solely on one component.
Question: My medical device startup is pre-FDA clearance — should I wait until after clearance to file patents?
Answer: No — filing patent applications before FDA clearance is not only appropriate but strongly advisable. Patent filing and FDA clearance are entirely separate processes with entirely different timelines. The patent system rewards early filing — the first to file gets priority. The FDA clearance process typically takes years — time during which competitors are developing, filing patents, and potentially establishing prior art that could limit your patent scope if you delay filing. Filing provisional patent applications early in your development process, before any public disclosures including investor pitches and scientific presentations, protects both your US patent rights and — critically — your international patent rights in absolute novelty jurisdictions.
Question: How do I protect innovations in minimally invasive surgical techniques and tools?
Answer: Minimally invasive surgical innovations present both device and method patent opportunities. The specific tool design — novel articulation mechanisms, specific degrees of freedom in robotic end effectors, novel tissue interaction geometries — can be protected through utility patent claims on the device structure. The specific surgical technique — the sequence of steps, specific tissue manipulation approach, the way the tool interacts with anatomy — can be protected through method of surgery claims, though these face enforcement challenges because the surgeon — rather than the device manufacturer — practices the method. I advise surgical device companies on claim strategies that capture the commercial value of both device and method innovations while maximizing enforceability against the parties who actually commercialize the technology.
Question: Can I patent a biomarker-based diagnostic test?
Answer: Biomarker-based diagnostic tests are one of the most complex areas of medical patent law post-Mayo. The Supreme Court's Mayo decision held that a correlation between a naturally occurring biomarker level and a medical condition is a law of nature not eligible for patent protection. What remains patentable are specific technical methods of measuring the biomarker — novel assay methods, specific probe designs, novel sample processing approaches, or specific algorithmic approaches to interpreting biomarker data that go beyond simply observing the natural correlation. The post-Mayo landscape requires very careful claim drafting that focuses on the technical implementation rather than the natural correlation itself.
Question: What is regulatory data exclusivity and how does it relate to patent protection for medical devices?
Answer: Regulatory data exclusivity — the period during which the FDA prevents competing products from relying on the original applicant's clinical data — is a form of market protection distinct from patent protection. For medical devices, regulatory exclusivity is less significant than for pharmaceuticals because FDA premarket approval does not rely on clinical data exclusivity in the same way that pharmaceutical NDA exclusivity does. Medical device market protection therefore depends more heavily on patent protection than drug market protection, making a strong patent portfolio even more important for medical device companies than for pharmaceutical companies that have multiple layers of regulatory and IP protection.
Question: How do I protect innovations in continuous monitoring devices like CGMs and wearable cardiac monitors?
Answer: Continuous monitoring devices involve layered innovations across sensor physics, signal processing, wireless communication, software algorithms, and clinical interpretation — each layer offering patent opportunities. The sensor element — the specific electrochemical, optical, or electromagnetic sensing mechanism — is typically the most technically defensible claim layer. The signal processing algorithms — noise filtering, calibration methods, artifact rejection — represent a second claim layer. The wireless data architecture, the AI-based interpretation algorithms, and the user interface design represent additional layers. I help continuous monitoring device companies develop comprehensive patent strategies that protect all these layers rather than patenting only the most obvious element of the device.
Question: Can I patent a new surgical technique if I am a surgeon rather than an engineer?
Answer: Surgeons are legitimate inventors and can obtain patents on novel surgical techniques and methods. The patent system does not require the inventor to be an engineer or to have a technical degree. However, medical method patents — methods of treating or diagnosing the human body — have specific practical enforcement limitations, since the Medical Procedures Defense under 35 U.S.C. § 287(c) exempts qualifying medical practitioners from liability for infringement of medical procedure patents for their personal practice. This means medical procedure patents are most effectively enforced against medical device manufacturers who provide tools that enable the procedure rather than against individual surgeons practicing it. I advise surgeon inventors on patent strategies that maximize the commercial value of their procedural innovations.
Question: How do I protect innovations in personalized medicine and precision diagnostics?
Answer: Personalized medicine — using genetic, genomic, or biomarker information to guide individual patient treatment decisions — represents one of the most legally complex areas of medical patent practice. The Mayo and Myriad Genetics decisions significantly restricted patent protection for genetic sequences and naturally occurring correlations between genetic markers and disease. But the specific technical tools of personalized medicine — the sequencing technologies, the bioinformatic analysis methods, the specific algorithms for interpreting multi-omic data, and the technical systems for delivering personalized treatment recommendations — remain patentable with proper claim drafting that focuses on the technical implementation rather than the natural genetic information being analyzed.
Question: What patent considerations apply to medical device software that learns and adapts post-deployment?
Answer: Adaptive medical device software — AI systems that continue learning from patient data after initial deployment — raises both patent and regulatory considerations that need to be addressed together. From a patent perspective, the initial algorithm training, the specific architecture designed for post-deployment adaptation, and the specific technical mechanisms by which the system updates itself are all potentially patentable. The challenge is that a patent application must enable the invention as filed — describing post-deployment learning requires disclosing the mechanism of adaptation, which may require more detailed specification drafting than static algorithm patents. FDA's predetermined change control protocol framework also affects how post-deployment adaptation is described and managed.
Question: Can I patent a method of manufacturing a biocompatible medical device material?
Answer: Manufacturing process patents for biocompatible materials and medical device components are valuable and patentable when the manufacturing process is novel and non-obvious. The specific process steps, temperature profiles, chemical compositions, surface treatment methods, or sterilization approaches that achieve the required biocompatibility, mechanical performance, or other device properties can be protected through method-of-manufacturing claims. Process patents in this space are particularly valuable because they can be difficult for competitors to design around without independently discovering the specific process innovations — especially when the process parameters are not derivable from the finished device's properties.
Question: How do medical device companies protect incremental innovations on cleared products?
Answer: Incremental improvements on cleared medical devices are protectable through continuation applications that pursue new claims based on original disclosures, and through new independent patent applications covering improvements made since the original filing. From a regulatory perspective, significant design changes to cleared devices may require a new 510(k) submission, a PMA supplement, or a De Novo request — but the regulatory burden of improvement clearance does not affect patentability of the underlying technical innovations. I help established medical device companies build comprehensive continuation and improvement patent strategies that keep pace with product evolution and competitive developments.
Question: What unique patent strategy considerations apply to Class III medical devices?
Answer: Class III medical devices — those requiring premarket approval for high-risk applications — face the longest development and regulatory timelines, making patent strategy particularly important and complex. The typical timeline from initial concept to commercial launch for a PMA device can be a decade or more — a significant portion of a 20-year patent term. Strategies for maximizing effective patent life for PMA devices include filing provisional applications as early as possible to defer the non-provisional filing and start the patent term as late as possible, pursuing continuation applications to maintain active prosecution throughout the regulatory process, and in some cases seeking patent term extension under 35 U.S.C. § 156 for delays attributable to the regulatory review process.
Question: Can my medical device patent protect uses of the device not described in FDA clearance?
Answer: Patent protection covers all uses of the patented device or method, not just FDA-cleared uses. A medical device company may have FDA clearance for a specific clinical indication while holding patents that cover the device's use across a broader range of applications. The converse is also true — a competitor's off-label use of a patented device can constitute infringement even if neither party has FDA clearance for that specific application. The relationship between the patent scope and the FDA clearance scope is an important strategic consideration I address with medical device clients in both portfolio building and enforcement planning.
Question: How do I protect a medical device innovation that was developed through a clinical research study?
Answer: Clinical research creates specific IP strategy considerations. The clinical protocol, data collected during the study, and clinical results are all potentially important for patent prosecution — they may provide evidence of utility, unexpected results supporting non-obviousness, or specific technical discoveries that constitute separate patentable innovations. However, clinical publications — research papers, conference presentations, FDA submissions — are public disclosures that can constitute prior art. I work with medical device researcher-inventors to ensure that patent applications are filed before clinical research publications occur, preserving both US and international patent rights while the clinical work is ongoing.
Question: What is the patent landscape for implantable neuromodulation devices?
Answer: Implantable neuromodulation — spinal cord stimulators, deep brain stimulators, peripheral nerve stimulators, and emerging closed-loop systems — is a heavily patented space dominated by Medtronic, Abbott, and Boston Scientific with growing activity from startups developing more targeted, more intelligent stimulation systems. The key patent opportunities in this space involve novel stimulation waveforms and patterns, closed-loop sensing and response systems that adapt stimulation based on physiological feedback, novel electrode array designs and placement strategies, and the AI algorithms that optimize stimulation parameters. My physics background — specifically electromagnetic theory and signal processing — informs my technical understanding of the physics underlying neuromodulation systems.
[ Related Services ]
Clients protecting medical device innovations often also work with me on:
[PCT International Patents] · [Freedom to Operate Opinions] · [IP Due Diligence] · [University & Research Institution IP] · [Startup IP Strategy]
[ Schedule a Free Consultation ]
Medical Device & Biotech Patent Services
Medical device and biotech patent prosecution sits at the intersection of physics, engineering, biology, and federal regulation — and getting it right requires an attorney who understands the technical substance of what you have built, not just the legal framework that governs its protection.
My physics degree from the University of Texas at Austin — where I studied quantum mechanics, classical dynamics, and electromagnetic theory — combined with hands-on experience in optics and photonic systems gives me the technical foundation to engage with diagnostic imaging systems, optical biosensors, wearable health monitors, surgical instruments, and AI-enabled clinical decision support tools at the engineering level that produces genuinely comprehensive patent protection.
For medical device companies the coordination between patent filing timing and FDA regulatory submissions — 510(k) clearance, PMA approval, De Novo classification — requires specific strategic attention that generalist IP counsel without medical device experience routinely misses. A disclosure in a 510(k) submission before a patent application is filed can permanently destroy international patent rights in absolute novelty jurisdictions. I advise medical device clients on patent filing strategy that coordinates with their regulatory pathway from the first conversation, ensuring that IP protection is established before regulatory submissions create prior art issues.
I work with Austin's health technology community — from UT Dell Medical School research spinouts developing novel diagnostic technologies to venture-backed medical AI companies building clinical decision support platforms to established medical device companies protecting next-generation innovations.
I offer a free 30-minute phone consultation to discuss your medical device or biotech innovation, assess its patentability across hardware, software, and method dimensions, and explain what a comprehensive IP strategy would look like for your specific technology and regulatory situation.
Call or text (512) 293-0710, email sconnolly@austin-patent-attorney.com, or fill out the form.
All consultations are confidential under attorney-client privilege.
Phone: 512-293-0710
Email: sconnolly@austin-patent-attorney.com
Location: Austin, Texas
Serving Austin, Round Rock, Cedar Park, Georgetown, and all of Central Texas.
USPTO matters are federal — I work with clients throughout Texas and nationwide.